Aardvark Therapeutics Shareholders Have Opportunity to Lead Securities Fraud Lawsuit
Investors who incurred losses in Aardvark Therapeutics now have an opportunity to lead a securities fraud class action lawsuit. The complaint alleges the company made materially false and misleading statements regarding its business.
The Law Offices of Frank R. Cruz announced on September 24, 2026, that investors who have suffered losses related to Aardvark Therapeutics, Inc. (AARD) have an opportunity to lead a securities fraud class action lawsuit.
The complaint alleges that between February 10, 2025, and May 14, 2026, the defendants made false and misleading statements and failed to disclose adverse information about the company's business, operations, and prospects. Specifically, it is alleged that the company misrepresented the safety of its drug candidate ARD-101, overstated its clinical, regulatory, and commercial outlooks, and consequently made misleading public statements.
Investors who experienced losses in Aardvark Therapeutics stock are encouraged by the law firm to contact them before the October 13, 2026, lead plaintiff deadline. The firm is seeking individuals to potentially lead the litigation.
The lawsuit claims that the company's public statements were materially false and misleading during the specified period. The law firm requests that interested parties provide their mailing address, telephone number, and the number of shares purchased when inquiring.